Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.54 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11463722 | 0.83 | IDO1 (0.57) | IDO1KDM4EALDH1A1NPC1TP53 | |
| SCHEMBL11453814 | 0.82 | PTGS2 (0.50) | TGFBR1KDM4EALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL7974992 | 0.73 | IDO1 (1.00) | IDO1TGFBR1KDM4EALDH1A1NPC1 | |
| SCHEMBL57525 | 0.73 | KDM4E (0.63) | TGFBR1DCTPP1KDM4EALDH1A1NPC1 | |
| SCHEMBL31607260 | 0.73 | KDM4E (0.63) | TGFBR1DCTPP1KDM4EALDH1A1NPC1 | |
| SCHEMBL31473547 | 0.73 | KDM4E (0.63) | TGFBR1DCTPP1KDM4EALDH1A1NPC1 | |
| SCHEMBL29484714 | 0.73 | KDM4E (0.63) | TGFBR1DCTPP1KDM4EALDH1A1NPC1 | |
| SCHEMBL28426539 | 0.72 | KDM4E (0.55) | TGFBR1DCTPP1KDM4EALDH1A1NPC1 | |
| SCHEMBL17343413 | 0.72 | KDM4E (0.51) | IDO1TGFBR1DCTPP1KDM4EALDH1A1 | |
| SCHEMBL20237398 | 0.71 | KDM4E (0.61) | TGFBR1DCTPP1KDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101580-B2 | Therapeutic agent for irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2012-01-24 | — | — | US | claimed |
| US-20090093415-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | ASTELLAS PHARMA INC. (JP) | 2009-04-09 | — | — | US | claimed |
| EP-1872795-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2008-01-02 | — | — | EP | claimed |
| US-8101580-B2 | Therapeutic agent for irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101580-B2 | Therapeutic agent for irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101580-B2 | Therapeutic agent for irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090093415-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | ASTELLAS PHARMA INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090093415-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | ASTELLAS PHARMA INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090093415-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | ASTELLAS PHARMA INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1872795-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2008-01-02 | — | — | EP | disclosed |
| EP-1872795-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093415-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | BRS3, VIPR2, BDKRB2 | IDO1 3042/4885TGFBR1 2575/4885DCTPP1 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.